rs3731211

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_058195.4(CDKN2A):​c.193+7291A>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.74 in 151,900 control chromosomes in the GnomAD database, including 41,619 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.74 ( 41619 hom., cov: 32)

Consequence

CDKN2A
NM_058195.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.197

Publications

45 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.81).
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.814 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDKN2ANM_058195.4 linkc.193+7291A>T intron_variant Intron 1 of 2 ENST00000579755.2 NP_478102.2 Q8N726-1
LOC124902130XR_007061436.1 linkn.5776A>T non_coding_transcript_exon_variant Exon 2 of 2
CDKN2ANM_001363763.2 linkc.-4+7973A>T intron_variant Intron 1 of 2 NP_001350692.1
CDKN2AXM_047422597.1 linkc.-4+7699A>T intron_variant Intron 1 of 2 XP_047278553.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDKN2AENST00000579755.2 linkc.193+7291A>T intron_variant Intron 1 of 2 1 NM_058195.4 ENSP00000462950.1 Q8N726-1

Frequencies

GnomAD3 genomes
AF:
0.740
AC:
112299
AN:
151782
Hom.:
41602
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.732
Gnomad AMI
AF:
0.613
Gnomad AMR
AF:
0.782
Gnomad ASJ
AF:
0.692
Gnomad EAS
AF:
0.787
Gnomad SAS
AF:
0.835
Gnomad FIN
AF:
0.767
Gnomad MID
AF:
0.687
Gnomad NFE
AF:
0.726
Gnomad OTH
AF:
0.720
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.740
AC:
112371
AN:
151900
Hom.:
41619
Cov.:
32
AF XY:
0.745
AC XY:
55307
AN XY:
74264
show subpopulations
African (AFR)
AF:
0.732
AC:
30351
AN:
41466
American (AMR)
AF:
0.782
AC:
11952
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.692
AC:
2400
AN:
3470
East Asian (EAS)
AF:
0.786
AC:
4064
AN:
5168
South Asian (SAS)
AF:
0.836
AC:
4026
AN:
4818
European-Finnish (FIN)
AF:
0.767
AC:
8121
AN:
10594
Middle Eastern (MID)
AF:
0.677
AC:
199
AN:
294
European-Non Finnish (NFE)
AF:
0.726
AC:
49187
AN:
67788
Other (OTH)
AF:
0.717
AC:
1512
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1538
3076
4614
6152
7690
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
854
1708
2562
3416
4270
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.730
Hom.:
22451
Bravo
AF:
0.737
Asia WGS
AF:
0.807
AC:
2807
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.81
CADD
Benign
7.9
DANN
Benign
0.73
PhyloP100
-0.20
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs3731211; hg19: chr9-21986847; COSMIC: COSV64266729; COSMIC: COSV64266729; API